A First-in-Human Phase I/IIa Trial of Personalised Tumour-Trained Lymphocytes (pTTL) Derived From Regional Lymph Nodes for the Treatment of Colorectal Cancer
Time: 11:30 am
day: Day Two
Details:
- Examining pTTL (personalised Tumour-Trained Lymphocytes), a novel adoptive T-cell therapy product targeting tumour neoantigens. It is applicable to any cancer type for which neoantigens can be identified
- Understanding how therapy is personalised, tailored for the patient’s own tumour and consists of autologuous neoantigen selected T-cells derived from regional lymph nodes (RLN)
- Unveiling a first-in-human trial of pTTL in stage IV colorectal cancer is ongoing
